Selective Aryl Ether LXRβ Agonists With Reduced Lipid Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies targeting liver X receptor (LXR) for treating Alzheimer's disease and other metabolic disorders often cause peripheral adverse lipid effects, while selective activation of LXRβ is believed to be more effective in addressing neurodegenerative diseases without these side effects.

Innovation Solution

Development of aryl and heteroaryl ether compounds that act as selective LXRβ agonists, which can be administered to treat inflammatory diseases and diseases related to defects in cholesterol and lipid metabolism, including Alzheimer's disease, by selectively activating LXRβ receptors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If dual LXRα/β small agonist molecules are used, then both LXRα and LXRβ are activated, but peripheral adverse lipid effects occur due to LXRα activation

Engineering Contradiction:

ImproveLXR activation coverageVSAvoidperipheral adverse lipid effects

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by creating selective LXRβ agonists that target specifically the LXRβ receptor subtype in the brain and peripheral tissues, while avoiding activation of LXRα in the liver and intestine. This selective targeting eliminates the harmful lipid effects associated with LXRα activation while preserving the beneficial neuroprotective effects of LXRβ activation.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the LXR receptor system into two distinct isoforms (LXRα and LXRβ) with different tissue distributions and functions. By developing compounds that selectively activate only LXRβ, the patent separates the beneficial neural effects from the harmful metabolic effects, allowing independent optimization of each receptor's activation.

Inventive Principle:

Principle #1Segmentation

2Object-affected harmful factors

If selective LXRβ agonists are developed, then neurodegenerative diseases are treated without peripheral adverse effects, but compound complexity increases

Engineering Contradiction:

Improveperipheral adverse lipid effectsVSAvoidcompound structure complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent employs parameter changes by systematically modifying molecular parameters (substituent groups, steric configurations, electronic properties) of the LXRβ agonist compounds. These parameter adjustments optimize the compounds' selectivity for LXRβ over LXRα, achieving the desired therapeutic effect with minimal peripheral effects while managing structural complexity through rational design.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3526196B1Aryl and heteroaryl ether derivatives as liver x receptor beta agonists

Publication Date: 2026.03.18 MERCK SHARP & DOHME LLC

AI summary

In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1,Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.